0001446847 false 0001446847 2020-09-29 2020-09-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares





Washington, D.C. 20549




Current Report Pursuant to 

Section 13 or 15(d) of the 

Securities Exchange Act of 1934


Date of Report (Date of Earliest Event Reported):

September 29, 2020



(Exact name of registrant as specified in its charter)


Delaware   001-34620   04-3404176
(State or other jurisdiction       (I.R.S. Employer
of incorporation)   (Commission File Number)   Identification Number)


100 Summer Street, Suite 2300        
Boston, Massachusetts       02110
(Address of principal        
executive offices)       (Zip code)


(617) 621-7722


(Registrant’s telephone number,

including area code)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:


Title of each class Trading Symbol(s) Name of each exchange on which
Class A common stock, $0.001 par value IRWD Nasdaq Global Select Market


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company o


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o






Item 2.05 Costs Associated with Exit or Disposal Activities.


On September 29, 2020, Ironwood Pharmaceuticals, Inc. (“Ironwood”) announced that it plans to discontinue development of IW-3718, its development program for the treatment of refractory gastroesophageal reflux disease. In connection with this decision, Ironwood announced its intention to reduce its workforce by approximately 100 full-time employees, or nearly 35% of its current workforce. This workforce reduction is expected to affect both field-based and home-office employees, including the relevant general and administrative support functions. Ironwood expects to substantially complete the reduction in its workforce in the first quarter of 2021. Following the changes, Ironwood expects to have approximately 210 full-time employees.


Ironwood estimates that, in connection with discontinuing development of IW-3718, it will incur aggregate charges of approximately $10 million to $12 million, primarily for one-time employee severance and benefit costs that are expected to be incurred in the fourth quarter of 2020.  Approximately 75% of these charges are expected to result in cash expenditures.


This Current Report on Form 8-K contains forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, including statements about Ironwood's expectations regarding its plan to discontinue development of IW-3718; the extent, impacted functions and timing of the planned workforce reduction; and the estimated financial impact, and the nature and timing thereof, associated with discontinuing IW-3718 development. Each forward-looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement. Applicable risks and uncertainties include those related to the difficulty of predicting the extent, financial impact or timing of the reduction in force and other costs related to discontinuing IW-3718 development, including the risk that the actual financial impact could vary materially from the outcomes anticipated; and the risks listed under the heading “Risk Factors” and elsewhere in Ironwood's Quarterly Report on Form 10-Q for the quarter ended June 30, 2020, and in Ironwood's subsequent SEC filings. These forward-looking statements speak only as of the date of this Current Report on Form 8-K, and Ironwood undertakes no obligation to update these forward-looking statements.







Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


    Ironwood Pharmaceuticals, Inc.
Dated: September 29, 2020   By: /s/ Gina Consylman
      Name: Gina Consylman
      Title: Senior Vice President, Chief Financial Officer